Hospital Acquired Infections Therapeutic Market Outlook 2031:
The global hospital acquired infections therapeutic market size was valued at USD 11.06 Billion in 2022 and is projected to reach USD 13.69 Billion by 2031, expanding at a CAGR of 2.4% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising R&D initiatives, high occurrence of hospital acquired infections and approval & launch of new therapies.
Hospital acquired infection (HAI), also known as nosocomial infection, is mainly caused by viral, bacterial, and fungal pathogens at the time of getting treatment or during patients’ stay in healthcare facilities.
High occurrence of the disease and rising resistance for antibiotic availability are increasing the demand for novel HAI therapeutics. Moreover, key market players are extensively investing in R&D activities for the development of new HAI drugs and other treatment equipment.
For instance, the US Food and Drug Administration (FDA), in June 2019, approved Zerbaxa (Ceftolozane and Tazobactam) as an expanded indication of Merck & Co., Inc.’s drug for the treatment of ventilator-associated bacterial pneumonia (HABP/VABP) and hospital acquired bacterial pneumonia.
Recently, chronic diseases such as heart disease, arthritis, cancer, and diabetes are becoming major health issues with rising occurrence across globe. This leads to rise in hospital admissions.
For instance, in November 2019, the New York State Department of Health published a data stating that around 40% of adults in New York suffered from chronic diseases, which has led to increase number of hospitalizations.
Hence, growing hospitalizations is expected to rise in more cases of HAIs that helps the market growth of HAIs therapeutics. Over the recent years, the prevalence of HAIs have decreased comparatively in developed economies owing to the strict norms and regulations implemented by government, mandating to boost the management of hygiene and cleanliness in the healthcare facilities.
In 2018, the Centers for Disease Control and Prevention (CDC) published a Healthcare-associated Infections Progress Report that stated, the central line-associated bloodstream infections were reduced by 9% in acute-care hospitals and also Clostridium difficile infections reduced by 12% in the US. The decline in the infection rate in the country is due to several improvement in healthcare management norms by the government.
Hospital Acquired Infections Therapeutic Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of chronic diseases with required to prolonged stay in hospitals is projected to drive the hospital acquired infections therapeutic market expansion.
- Poor training and infection control practices, low expenditure on healthcare, and poor hospital infrastructure are anticipated to push the hospital acquired infections therapeutic market growth during the forecast period.
- Environmental factors such as infected materials and bacterial load in hospitals and presence of other diseases are anticipated to fuel the market growth.
- Introduction of strict regulations from government bodies to ensure clean and healthy management of hospitals especially in the developed regions is key factors expected to hamper the hospital acquired infections therapeutic market growth.
- Rising precautionary measures and increasing awareness among staff and professionals in hospitals are projected to impede the market growth.
Scope of Hospital Acquired Infections Therapeutic Market Report
The report on the global hospital acquired infections therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hospital Acquired Infections Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016 – 2021
|
|
Forecast Period
|
2023 – 2032
|
|
Segmentation
|
Drug Classes (Antibacterial Drugs [Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, and Others], Antiviral Drugs, and Antifungal Drugs), Infection Types (Bloodstream Infections, Ventilator-associated Pneumonia, Urinary Tract Infections, Surgical Site Infections, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Ltd., AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Allergan Plc.
|
Hospital Acquired Infections Therapeutic Market Segment Insights
Antibacterial drugs segment is expected to expand at a rapid pace
On the basis of drug classes, the hospital acquired infections therapeutic market is segmented into antibacterial drugs, antiviral drugs, and antifungal drugs. The antibacterial drugs segment is further divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others.
The antibacterial drugs segment is expected to hold a key share of the market during the forecast period due to large number of HAIs are caused by bacteria. The drug type is considered to be one of the primary treatment and most commonly adopted for the disease treatment. Patients who are affected with gram-positive and gram-negative pathogens are treated with antibiotics.
For multidrug-resistant pathogens treatment, empiric antibiotic therapy is initially considered and is highly used for avoiding complications such as bloodstream infections, renal damage, and pyelonephritis.
Surgical site infections segment is projected to hold a key market share
Based on infection types, the hospital acquired infections therapeutic share market is segmented into bloodstream infection (BSI), Pneumonia, urinary tract infection (UTI), and surgical site infection (SSI). The SSIs segment dominated the market in 2020 and is expected to hold a key share of the market during the forecast period owing to growing number of SSI cases subsequently and increasing number of surgical procedures.
According to the CDC, each year nearly around 27 million surgical procedures are performed out of which around 5% of patients got SSIs in the US. Due to this reason, the patient’s hospitalization is normally lasted for 7 to 10 days and average cost is around USD 3,000 per patient.
On the other hand, the UTIs segment is anticipated to expand at a rapid pace during the forecast period due to increasing cases of UTI and growing awareness among people in developed countries. Kidney, ureters, urethra, and bladder are affected by UTIs and around 40% of the population have had the experience of UTI condition for several period of time.
As per a report by National Healthcare Safety Network, the common type of UTI is Catheter-associated UTIs (CA-UTIs) and as per CDC 2017 data, CA-UTIs accounted for around two-thirds of the UTIs. Furthermore, introducing novel drugs for UTI is a major factor responsible for fuel the HAIs therapeutics market growth.
Europe is anticipated to dominate the market
On the basis of regions, the hospital acquired infections therapeutic market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Europe is anticipated to dominate the market at an impressive CAGR during the forecast period.
The regional market growth can be attributed to occurrence of HAIs in this region and rising introduction of novel HAI therapeutic drugs owing to presence of local key players such as GlaxoSmithKline Plc., F. Hoffmann-La Roche AG., Allergan Plc., and Bayer AG.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to growing occurrence of chronic diseases in emerging countries such as India and China, which lead to rise in the number of hospitalization in these countries.
For instance, Globocan published a data in 2018, in China around 4,285,000 new cases of cancer were diagnosed. Hence, rising rate of HAIs with growing hospitalizations in the region is projected to increase the demand for HAI therapeutic market in Asia Pacific.
Segments
The global hospital acquired infections therapeutic market has been segmented on the basis of
Drug Classes
- Antibacterial Drugs
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- Others
- Antiviral Drugs
- Antifungal Drugs
Infection Types
- Bloodstream Infections (BSI)
- Ventilator-associated Pneumonia
- Urinary Tract Infections (UTI)
- Surgical Site Infections (SSI)
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the hospital acquired infections therapeutic market include Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Allergan Plc.
Some of these major players are constantly focusing on business strategies including as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance, in March 2017, a US-based multinational pharmaceutical company, Pfizer Inc. has introduced its drug Zavicefta (Ceftazidime-Avibactam) in the UK and Germany. This drug was approved for different indications including hospital-acquired pneumonia (HAP).
Request For Customization
Enquiry Before Buying
Speak With Analyst
